MARKET

GRFS

GRFS

Grifols
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.29
-0.07
-0.46%
After Hours: 15.29 0 0.00% 16:00 09/24 EDT
OPEN
15.26
PREV CLOSE
15.36
HIGH
15.35
LOW
15.15
VOLUME
330.15K
TURNOVER
--
52 WEEK HIGH
20.49
52 WEEK LOW
14.01
MARKET CAP
3.92B
P/E (TTM)
13.11
1D
5D
1M
3M
1Y
5Y
New Strong Sell Stocks for September 22nd
Zacks.com · 2d ago
European markets mixed as growth fears weigh on global sentiment; UK retail sales fall; Euro zone inflation surges
European markets were cautiously higher on Friday as global investors continued to weigh the prospect of slowing economic growth.
CNBC.com · 09/17 09:57
BRIEF-Grifols' Co-CEO Says Biotest Acquisition To Boost EBITDA By 300 Mln Euros In 2024, 600 Mln Euros In 2026
* ACCESS TO PLASMA CRUCIAL, COMPANY PLANS TO OPEN 20 CENTRES PER YEAR OVER NEXT 3-4 YEARS
Reuters · 09/17 09:22
Grifols Buys Biotest as Creat Pushed to Exit Blood-Plasma Stakes
(Bloomberg) -- Grifols SA agreed to buy Biotest AG for about 1.6 billion euros ($1.9 billion), pouncing after U.S. regulators pushed back on Chinese shareholder Creat Group Corp.’s expansion into the blood-plasma industry.Grifols offered 43 euros for each ...
Bloomberg · 09/17 07:57
Grifols acquires Tiancheng Pharmaceutical Holdings, the largest shareholder of Biotest, to increase patients' access to plasma therapies
Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ:GRFS), a global healthcare leader with a track record of more than 110 years dedicated to enhancing people's health and well-being and a forerunner in plasma-derived medicines, transfusion diagnostics and hospital phar...
PR Newswire · 09/17 07:15
Grifols to Acquire Controlling Stake in German Rival Biotest
MT Newswires · 09/17 05:08
Grifols Sells Off With Effects of Pandemic
GuruFocus News · 08/23 18:11
Velanne Asset Management Ltd Buys Grifols SA, Burford Capital, Raytheon Technologies Corp, ...
GuruFocus News · 08/13 19:38
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GRFS. Analyze the recent business situations of Grifols through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GRFS stock price target is 27.03 with a high estimate of 34.96 and a low estimate of 19.09.
EPS
Institutional Holdings
Institutions: 268
Institutional Holdings: 101.55M
% Owned: 39.61%
Shares Outstanding: 256.35M
TypeInstitutionsShares
Increased
64
8.03M
New
15
2.00M
Decreased
47
11.88M
Sold Out
25
1.76M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.45%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman
Victor Grifols Roura
Co-Chief Executive Officer/Executive Director
Victor Grifols Deu
Co-Chief Executive Officer/Executive Director
Raimon Grifols Roura
Non-Executive Vice Chairman
Thomas Glanzmann
Chief Financial Officer
Alfredo Arroyo Guerra
Corporate Executive
Joel Abelson
Corporate Executive
Albert Coma-Cros
Corporate Executive
Alberto Grifols Roura
Corporate Executive
Chris Healey
Corporate Executive
Miguel Pascual Montblanch
Chief Human Resource Officer
Mateo Borras Humbert
Chief Technology Officer
Javier Sueiras Gil
Vice President
Vicente Blanquer Torre
Vice President
Matt Murawski
Vice President
Nuria Pascual Lapena
Vice President
Maria Rione
General Counsel
David Bell
Managing Director
Luis Twose Garcon
Other
Daniel Fleta Coit
Other
Lafmin Morgan
Secretary
Nuria Martin Barnes
Assistant Secretary/Director
Tomas Daga Gelabert
Lead Director/Independent Director
Inigo Sanchez Asiain Mardones
Director
Ramon Riera Roca
Independent Director
James Costos
Independent Director
Marla Elizabeth Salmon
Independent Director
Enriqueta Felip Font
Independent Director
Steven Mayer
Independent Director
Carina Szpilka Lazaro
Independent Director
Belen Villalonga Morenes
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 0.359835
06/03/2021
--
Special Dividend USD 0.0101
06/03/2021
--
Dividend USD 0.143166
10/30/2020
10/31/2019
Dividend USD 0.169716
12/02/2019
05/29/2019
Dividend USD 0.175638
06/07/2019
11/07/2018
Dividend USD 0.22789
11/30/2018
05/25/2018
Dividend USD 0.250975
06/01/2018
--
Dividend USD 0.212979
12/01/2017
--
Dividend USD 0.163528
05/30/2017
--
Dividend USD 0.193644
12/05/2016
--
Dividend USD 0.162059
06/02/2016
--
Dividend USD 0.384765
12/10/2015
--
Dividend USD 0.341846
06/08/2015
--
Dividend USD 0.312792
12/04/2014
05/30/2014
Dividend USD 0.286887
06/05/2014
05/24/2013
Dividend USD 0.258668
06/05/2013
05/17/2013
Dividend USD 0.01283
05/29/2013
About GRFS
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.

Webull offers kinds of Grifols SA - ADR stock information, including NASDAQ:GRFS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRFS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GRFS stock methods without spending real money on the virtual paper trading platform.